INFevo
Category: AI in Biotech / Drug Discovery
Beijing AI-native biotech, incubated by XtalPi (2228.HK), building AI virtual cell foundation models (OCOO) coupled with automated wet-lab loops for target discovery and drug screening. INFevo was founded in 2025. Based in Beijing, China. Total funding raised: $14.0M. Latest round: Pre-Series A. Key investors include Xinglian Capital, Prosperity7 Ventures, Huagai Capital, Huakong Fund, DT Capital, Shunwei Capital, HongShan (Sequoia China), Songhe Capital.
- Founded
- 2025
- Headquarters
- Beijing, China
- Total funding
- $14.0M
Value proposition
Predict cellular responses to drug, gene and other perturbations in silico before wet-lab work, so researchers can prioritize targets and candidate molecules and spend experimental capacity on the most promising hypotheses.
Products and solutions
OCOO virtual cell foundation models (OCOO-T is transcriptome-based), automated cell experiment platform (culture, perturbation, multi-omics readout, QC), The Popper Project (TPP) hypothesis-mining engine, Karl Workbench research workbench (closed beta)
Unique value
A dual-driven loop of a foundation model and high-throughput automated experiments, organized around 'Recursive Scientific Discovery' (RSD), which stores hypotheses, methods and results in structured form for reuse.
Target customer
Pharmaceutical companies, hospitals and research institutes
Industries served
Drug discovery, life sciences research, clinical translation
Technology advantage
OCOO-T reports PDCorr 0.952 on Tahoe100M, PDS_cos 0.833 on Replogle and DEOver 0.760 on PBMC in its preprint, ahead of the STATE, PerturbDiff and CellFlow baselines (company-reported). Karl Workbench with DeepSeek ranked first on SciAgentArena single-cell and spatial omics (company-reported). XtalPi's molecular design and automated synthesis capabilities are complementary.
How they differentiate
Combines a virtual cell model with an in-house automated wet-lab loop and an agentic hypothesis engine (TPP/Karl), backed by XtalPi's molecular design and automation stack.
Main competitors
Noetik (US), Xaira Therapeutics (US), Deep Cell / 深度细胞 (China), Yuanshi Technology / 元示科技 (China)
Key partnerships
XtalPi (incubator and ecosystem partner), Peking University First Hospital-led Beijing Key Laboratory for hepatobiliary-pancreatic tumor organoids and intelligent diagnosis, Angpu Bio (strategic collaboration on a genetic-disease R&D platform, Aug 2026)
Major milestones
2025 founded as an XtalPi incubation, 2026-06 angel round and OCOO-T preprint, 2026-07 launch of The Popper Project, 2026-08 joined the Peking University First Hospital organoid key lab and signed with Angpu Bio, 2026-09 Karl Workbench closed beta, 2026-10 SciAgentArena first place, 2026-11 Pre-A of RMB 100M+.
Growth metrics
Two rounds within five months (angel in June 2026, Pre-A in November 2026). No revenue or customer figures disclosed.
Market positioning
Describes its Pre-A as the largest single financing round among Chinese virtual-cell companies (company claim). Early-stage AI4S / AI biology platform in a fast-funding virtual-cell segment alongside Noetik, Xaira, GenBio AI and Arc Institute's Virtual Cell Initiative.
Geographic focus
China, with a global ambition
Patents and IP
OCOO-T preprint (June 2026); no patents found publicly
Latest news about INFevo
More AI in Biotech / Drug Discovery companies
Official website: https://infevo.ai/